# A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

> **NCT03313180** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 444 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT03313180
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-01-25
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03313180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03313180, "A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03313180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*